Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765119 | 0.97 | IDO1 (0.52) | IDO1TAAR1LOXL2HRH3HTR2A | |
| SCHEMBL18494541 | 0.87 | IDO1 (0.41) | IDO1TAAR1LOXL2HTR2AABAT | |
| SCHEMBL27824736 | 0.87 | IDO1 (0.41) | IDO1TAAR1HTR2AABATENPP2 | |
| SCHEMBL11437281 | 0.84 | IDO1 (0.43) | IDO1TAAR1LOXL2HRH3HTR2A | |
| SCHEMBL63392 | 0.83 | LOXL2 (0.47) | TAAR1LOXL2HRH3ABATPNMT | |
| SCHEMBL24264540 | 0.82 | IDO1 (0.46) | IDO1TAAR1AGXTABATENPP2 | |
| SCHEMBL16635217 | 0.82 | IDO1 (0.41) | IDO1TAAR1HTR2ATACR1 | |
| SCHEMBL1363469 | 0.82 | PNMT (0.46) | IDO1TAAR1LOXL2PNMT | |
| SCHEMBL2039301 | 0.82 | LOXL2 (0.42) | IDO1TAAR1LOXL2 | |
| SCHEMBL1363875 | 0.82 | TACR1 (0.44) | IDO1TAAR1LOXL2HTR2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4636054-A2 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRvana Sciences Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3959292-B1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025068371-A1 | INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-04-03 | — | — | WO | disclosed |
| EP-3959293-B1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20220249708-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220249707-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3959292-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRvana Sciences Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3959293-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRvana Sciences Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020236818-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236828-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | NIRVANA SCIENCES INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-8796300-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2496704-A1 | THERAPEUTIC COMPOUNDS | Rutgers, The State University of New Jersey (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057126-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-05-12 | — | — | WO | disclosed |
| CN-101990401-A | Dual pharmacophores-PDE 4-muscarinic antagonists | GLAXO GROUP LTD | 2011-03-23 | — | — | CN | disclosed |
| CN-101983010-A | Dual pharmacophores-pde4-muscarinic antagonistics | GLAXO GROUP LTD | 2011-03-02 | — | — | CN | disclosed |
| CN-101983009-A | Dual pharmacophores-PDE 4-muscarinic antagonists | GLAXO GROUP LTD | 2011-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | CCNY, MKI67, MCL1 | IDO1 2612/4885TAAR1 4425/4885LOXL2 3859/4885 |
| US-20220249707-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | AQP4, CLSPN, CHLSN | IDO1 2350/4885TAAR1 4410/4885LOXL2 4114/4885 |
| US-20220249708-A1 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | MB, LNPEP, BCR | IDO1 1621/4885TAAR1 4499/4885LOXL2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.